Focus Stocks
Trading Idea: Key levels for GlaxoSmithKline
Published on Thursday, 06 September 2012 07:48 Written by TradersHuddle Wire
New York, September 6th (TradersHuddle.com) - Shares of GlaxoSmithKline plc (NYSE:GSK) are trading very close to calculated support at $43.77 with price action closing at just $45.30 and placing the stock near levels where traders will start paying attention.
GlaxoSmithKline's stock range is defined by its calculated support defined at $43.77 and by the resistance level at $47.40, which should be used by traders planning their trades. These support and resistance levels are based on a peaks and troughs algorithm of the stock's price action.
Traders wanting to establish a position should pay close attention to GlaxoSmithKline's price action, and establish it as close to support as possible, but only after buying materializes. Traders should understand that the resistance point at $47.40 might limit their upside, however, if the stock breaks resistance, it could be a good point to add to the position.
GlaxoSmithKline plc (NYSE:GSK) is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. Its over the counter medicines and health related consumer products are marketed under brand names like Panadol, Nicorette, Breathe Right, Tums, Aquafresh, and Sensodyne among others.
Related Articles
- GlaxoSmithKline Is Near a Key Resistance Area
- BREO™ ELLIPTA™ gains US approval for the treatment of COPD
- Trading Idea: - Is GlaxoSmithKline close to Resistance?
- GlaxoSmithKline Is Moving Above Resistance
- GlaxoSmithKline Is Near a Key Resistance Area
- GlaxoSmithKline Is Moving Above Resistance
- GlaxoSmithKline CFO Interviewed on Q1 2013 Financial Results
- GlaxoSmithKline Is Near a Key Resistance Area
- Above Resistance: GlaxoSmithKline
- FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD
Related Partner Headlines
- GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK) - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- Buzz on Sarepta's Eteplirsen From London Duchenne Meeting - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Health Care Winner - TheStreet.com
- United Therapeutics Could Lose The Battle For PAH Therapies - TheStreet.com
- A Prescription for Election Fever - TheStreet.com
- GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard - TheStreet.com
- How to Hedge Profits in Sarepta Therapeutics - TheStreet.com
- Lazard Analyst Note on Sarepta Therapeutics Is Generating Buzz - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,335.28 Trade time:4:36PM EDT Value change:▼19.12 (-0.12%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,666.29 Trade time:4:36PM EDT Value change:▼1.18 (-0.07%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,496.43 Trade time:5:15PM EDT Value change:▼2.54 (-0.07%)In The Wires
-
Online Food Delivery Now Available at SportsFanPlayground.com -
AT&T Statement on Response to Oklahoma Tornado -
GeckoSystems, an AI Mobile Robot Co., Reports First Net Profits -
iPhone 5 Accessories On Sale at SportsFanPlayground.com -
North Texas Fence and Deck Introduces Residential and Commercial Fence Builder Service in Plano, Texas -
G4S Moves Offices to Downtown Indianapolis Bringing Jobs and People to the Circle City -
Long Awaited Web Development Toolkit Demo Released By ARME Realty.com -
New Mt. Everest Budget Tibet Tour 2013, Freshly Updated by Local Tibet Travel Agency








